Short answer
Pfizer Inc (PFE) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 28, 2025. Quarterly revenue was $16.7B (down 5.9% year over year) with net income of $3.5B.
Q3 2025 key financials · XBRL
- Revenue
- $16.7B
- −5.9% YoY · +13.7% QoQ
- Net income
- $3.5B
- −20.7% YoY · +21.7% QoQ
- EPS (diluted)
- $0.62
- −21.5% YoY · +21.6% QoQ
Source: XBRL data from the Pfizer Inc (PFE) Q3 2025 10-Q on SEC EDGAR. USD.
Pfizer Inc Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $16.7B Q3 2025, down 6% YoY from $17.7B, driven by $1.3B operational decline mainly due to Paxlovid (-55%) and Comirnaty (-20%)
- Income from continuing ops before tax $3.3B Q3 2025 vs $4.7B Q3 2024; operating margin approx. 19.8% Q3 2025 vs 26.5% Q3 2024 (revenue-based approximation)
- Best segment: Biopharma revenue $16.3B Q3 2025, down 6%; worst product: Paxlovid revenue $1.2B Q3 2025, down 55% operationally YoY
- Operating cash flow $6.4B YTD 2025 up from $6.0B YTD 2024; Haleon investment sale proceeds $6.3B used for capital allocation
- Outlook: Strategic focus on R&D productivity, margin expansion, digital enablement; expects 2025 COVID product revenues lower due to reduced demand and new pricing policies; highlighted cost savings programs targeting $5.7B net savings through 2027
Risk Factors
- New product withdrawal risk: Voluntary withdrawal of Oxbryta in 2024 due to safety concerns, with EMA maintaining suspension and FDA review ongoing
- Material regulatory update: IRA Medicare Part D Redesign in 2025 expected to reduce revenue by ~$1 billion, impacting pricing and manufacturer discounts
- Legal/compliance risk: Increased charges of $191M (Q3) and $755M (YTD) for legal matters, mainly product liability expenses in 2025
- Operational risk: Lower COVID-19 product demand (Paxlovid down 55% Q3, 57% YTD YoY) due to reduced infection rates affecting near-term revenue
- Financial risk: $6.3 billion proceeds from Haleon investment sale used to support capital priorities; $7 billion revolving credit facility available, largely unused
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pfizer Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.